[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 26 of about 26
1. Ozaki K, Narama I: Merkel cell carcinoma in a cat. J Vet Med Sci; 2009 Aug;71(8):1093-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Merkel cell carcinoma in a cat.
  • The proliferating pattern of tumor cells was solid but also trabecular or cord-like in some areas, and lined with small cells resembling mature lymphocytes or basal cells.
  • This is the first report describing now cytokeratin 20 was clearly beneficial for the differential diagnosis of feline Merkel cell carcinoma.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19721365.001).
  • [ISSN] 0916-7250
  • [Journal-full-title] The Journal of veterinary medical science
  • [ISO-abbreviation] J. Vet. Med. Sci.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Keratin-20; 0 / Synaptophysin
  •  go-up   go-down


2. Gerstenblith MR, Goldstein AM, Tucker MA: Hereditary genodermatoses with cancer predisposition. Hematol Oncol Clin North Am; 2010 Oct;24(5):885-906
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this article hereditary genodermatoses with cancer predisposition are reviewed, including nevoid basal cell carcinoma syndrome, neurofibromatosis types 1 and 2, tuberous sclerosis complex, xeroderma pigmentosum, and dyskeratosis congenita.
  • Early recognition and diagnosis allows for close follow-up and surveillance for associated malignancies.
  • [MeSH-major] Genetic Predisposition to Disease. Neoplastic Syndromes, Hereditary / genetics. Skin Diseases / genetics
  • [MeSH-minor] Animals. Basal Cell Nevus Syndrome / genetics. Basal Cell Nevus Syndrome / therapy. Genetic Testing. Humans. Melanoma / genetics. Melanoma / therapy. Neurofibromatoses / genetics. Neurofibromatoses / therapy. Xeroderma Pigmentosum / genetics. Xeroderma Pigmentosum / therapy

  • Genetic Alliance. consumer health - Hereditary Cancer.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published by Elsevier Inc.
  • [Cites] Neurology. 2003 Jan 14;60(1):130-2 [12525736.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):507-16 [16421428.001]
  • [Cites] Curr Biol. 2003 Aug 5;13(15):1259-68 [12906785.001]
  • [Cites] Am J Cardiol. 2003 Aug 15;92(4):487-9 [12914889.001]
  • [Cites] J Invest Dermatol. 2003 Sep;121(3):478-81 [12925203.001]
  • [Cites] J Pediatr. 2003 Nov;143(5):620-4 [14615733.001]
  • [Cites] Annu Rev Genet. 2003;37:67-90 [14616056.001]
  • [Cites] Hum Genet. 2004 Feb;114(3):284-90 [14605872.001]
  • [Cites] Hum Mutat. 2004 Jun;23(6):630 [15146471.001]
  • [Cites] Am J Hum Genet. 2004 Aug;75(2):231-9 [15190457.001]
  • [Cites] Acta Neurol Taiwan. 2004 Mar;13(1):10-3 [15315295.001]
  • [Cites] BJU Int. 2004 Oct;94(6):853-7 [15476522.001]
  • [Cites] Am J Hum Genet. 1967 Jan;19(1):12-22 [4960000.001]
  • [Cites] Arch Dermatol. 1968 Jul;98(1):1-6 [4968649.001]
  • [Cites] Arch Dermatol. 1978 May;114(5):732-8 [646394.001]
  • [Cites] J Med Genet. 1978 Oct;15(5):352-6 [739524.001]
  • [Cites] Clin Exp Dermatol. 1985 Nov;10(6):562-5 [4092358.001]
  • [Cites] Arch Dermatol. 1987 Feb;123(2):241-50 [3545087.001]
  • [Cites] Genes Dev. 2001 Jun 1;15(11):1383-92 [11390358.001]
  • [Cites] J Med Genet. 2001 May;38(5):347-9 [11403047.001]
  • [Cites] Neurology. 2001 Jun 12;56(11):1433-43 [11409413.001]
  • [Cites] Am J Hum Genet. 2001 Oct;69(4):765-73 [11500805.001]
  • [Cites] Am J Hum Genet. 2001 Oct;69(4):774-9 [11500806.001]
  • [Cites] Genes Dev. 2001 Dec 1;15(23):3059-87 [11731473.001]
  • [Cites] Respir Med. 2002 Jan;96(1):1-6 [11863203.001]
  • [Cites] Eur J Paediatr Neurol. 2002;6(1):15-23 [11993952.001]
  • [Cites] J Natl Cancer Inst. 2002 Jun 19;94(12):894-903 [12072543.001]
  • [Cites] Nat Genet. 2002 Jul;31(3):306-10 [12068298.001]
  • [Cites] Nature. 2002 Aug 22;418(6900):892-7 [12192414.001]
  • [Cites] Science. 2002 Aug 30;297(5586):1559-61 [12202832.001]
  • [Cites] Am J Hum Genet. 2002 Oct;71(4):715-23 [12235555.001]
  • [Cites] Cancer Res. 2002 Oct 15;62(20):5645-50 [12384518.001]
  • [Cites] J Child Neurol. 2002 Aug;17(8):585-91; discussion 602-4, 646-51 [12403557.001]
  • [Cites] Lancet Oncol. 2002 Nov;3(11):653-4 [12424065.001]
  • [Cites] Ann Hum Genet. 2003 Jan;67(Pt 1):87-96 [12556239.001]
  • [Cites] J Urol. 2003 May;169(5):1635-42 [12686801.001]
  • [Cites] Am J Hum Genet. 2003 May;72(5):1288-92 [12660952.001]
  • [Cites] Lancet. 2003 Apr 19;361(9366):1348-9 [12711473.001]
  • [Cites] Lancet. 2003 May 3;361(9368):1552-4 [12737880.001]
  • [Cites] Oncogene. 2003 May 19;22(20):3053-62 [12789280.001]
  • [Cites] J Med Genet. 2003 Jun;40(6):459-63 [12807969.001]
  • [Cites] Arch Dermatol. 2003 Jun;139(6):816-7 [12810525.001]
  • [Cites] Am J Hum Genet. 2003 Aug;73(2):301-13 [12844286.001]
  • [Cites] Am J Med Genet. 1994 Oct 1;52(4):450-61 [7747758.001]
  • [Cites] Arch Dermatol. 1995 Aug;131(8):904-8 [7632061.001]
  • [Cites] Epilepsy Res. 2000 Feb;38(2-3):151-60 [10642043.001]
  • [Cites] Hum Mutat. 2000;15(6):541-55 [10862084.001]
  • [Cites] J Natl Cancer Inst. 2000 Jun 21;92(12):1006-10 [10861313.001]
  • [Cites] Hum Mutat. 2000 Jul;16(1):89-90 [10874314.001]
  • [Cites] Dermatology. 2000;200(4):299-302 [10894959.001]
  • [Cites] J Natl Cancer Inst. 2000 Aug 2;92(15):1260-6 [10922411.001]
  • [Cites] J Child Neurol. 2000 Oct;15(10):652-9 [11063078.001]
  • [Cites] J Neurosurg. 1995 Oct;83(4):596-9 [7545742.001]
  • [Cites] Nat Genet. 1995 Sep;11(1):90-2 [7550323.001]
  • [Cites] J Neurobiol. 1995 Aug;27(4):535-52 [7561832.001]
  • [Cites] J Neurosurg. 1996 Jan;84(1):20-8 [8613831.001]
  • [Cites] Nat Genet. 1996 Jan;12(1):85-7 [8528259.001]
  • [Cites] Nat Genet. 1996 Jan;12(1):97-9 [8528263.001]
  • [Cites] J Clin Oncol. 1999 Oct;17(10):3245-51 [10506626.001]
  • [Cites] AMA Arch Derm Syphilol. 1951 Jan;63(1):73-84 [14789211.001]
  • [Cites] AMA Arch Derm. 1959 Jan;79(1):67-77; discussion 77-80 [13605278.001]
  • [Cites] N Engl J Med. 1960 May 5;262:908-12 [13851319.001]
  • [Cites] Genet Med. 2004 Nov-Dec;6(6):530-9 [15545751.001]
  • [Cites] J Child Neurol. 2004 Sep;19(9):650-7 [15563010.001]
  • [Cites] Otol Neurotol. 2005 Jan;26(1):93-7 [15699726.001]
  • [Cites] Hum Mutat. 2005 Apr;25(4):353-9 [15776433.001]
  • [Cites] Eur J Hum Genet. 2005 Jun;13(6):731-41 [15798777.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Sep;44(1):10-8 [15880589.001]
  • [Cites] Br J Neurosurg. 2005 Feb;19(1):5-12 [16147576.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Sep;14(9):2208-12 [16172233.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7168-77 [16192601.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Oct;14(10):2384-90 [16214921.001]
  • [Cites] J Natl Cancer Inst. 2005 Oct 19;97(20):1507-15 [16234564.001]
  • [Cites] J Invest Dermatol. 2006 Mar;126(3):660-6 [16397522.001]
  • [Cites] Ann Neurol. 2006 Mar;59(3):490-8 [16453317.001]
  • [Cites] Ann Intern Med. 2006 Jun 6;144(11):842-9 [16754926.001]
  • [Cites] Am J Ophthalmol. 2006 Jun;141(6):1068-1077 [16765675.001]
  • [Cites] Am J Surg Pathol. 2006 Aug;30(8):1047-51 [16861979.001]
  • [Cites] Am J Kidney Dis. 2006 Sep;48(3):e27-9 [16931204.001]
  • [Cites] Nat Genet. 1995 May;10(1):114-6 [7647780.001]
  • [Cites] J Dent Res. 2006 Sep;85(9):859-63 [16931872.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):9818-28 [17047042.001]
  • [Cites] Kidney Int. 2006 Nov;70(10):1777-82 [17003820.001]
  • [Cites] Ann Neurol. 2006 Nov;60(5):528-39 [17120248.001]
  • [Cites] Eur J Hum Genet. 2007 Feb;15(2):131-8 [16957683.001]
  • [Cites] J Med Genet. 2007 Feb;44(2):99-106 [16905682.001]
  • [Cites] J Med Genet. 2007 Feb;44(2):81-8 [17105749.001]
  • [Cites] Curr Opin Neurol. 2007 Apr;20(2):142-50 [17351483.001]
  • [Cites] Hum Mutat. 2007 May;28(5):495-505 [17279550.001]
  • [Cites] J Invest Dermatol. 2007 May;127(5):1234-43 [17218939.001]
  • [Cites] Neuroscience. 2007 Apr 14;145(4):1388-96 [17276014.001]
  • [Cites] J Am Acad Dermatol. 2007 Aug;57(2):189-202 [17637444.001]
  • [Cites] Blood. 2007 Sep 1;110(5):1439-47 [17468339.001]
  • [Cites] Nat Genet. 2007 Sep;39(9):1120-6 [17704776.001]
  • [Cites] Br J Cancer. 2007 Sep 17;97(6):832-6 [17848914.001]
  • [Cites] Chest. 2007 Sep;132(3):798-808 [17573495.001]
  • [Cites] Genes Chromosomes Cancer. 2008 Feb;47(2):175-84 [18023021.001]
  • [Cites] N Engl J Med. 2008 Jan 10;358(2):140-51 [18184959.001]
  • [Cites] Cell. 1987 Jun 5;49(5):589-94 [2884037.001]
  • [Cites] Nature. 1987 Sep 17-23;329(6136):246-8 [2888021.001]
  • [Cites] N Engl J Med. 1988 Mar 17;318(11):684-8 [3125435.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1989 Dec;68(6):725-8 [2594320.001]
  • [Cites] Acta Neuropathol. 1989;79(2):137-43 [2596263.001]
  • [Cites] Arch Ophthalmol. 1990 Mar;108(3):328-9 [2310328.001]
  • [Cites] Neurofibromatosis. 1988;1(3):172-8 [3152465.001]
  • [Cites] Ann N Y Acad Sci. 1991;615:125-7 [2039137.001]
  • [Cites] Ann N Y Acad Sci. 1991;615:367-9 [2039161.001]
  • [Cites] Ann N Y Acad Sci. 1991;615:8-16 [2039170.001]
  • [Cites] Lancet. 1992 Mar 7;339(8793):581-2 [1347096.001]
  • [Cites] Neuron. 1992 Mar;8(3):415-28 [1550670.001]
  • [Cites] J Med Genet. 1992 Dec;29(12):841-6 [1479598.001]
  • [Cites] J Med Genet. 1992 Dec;29(12):847-52 [1479599.001]
  • [Cites] Q J Med. 1992 Aug;84(304):603-18 [1484939.001]
  • [Cites] Cancer Metastasis Rev. 1994 Mar;13(1):67-89 [8143346.001]
  • [Cites] Science. 1994 Apr 15;264(5157):436-40 [8153634.001]
  • [Cites] Arch Dermatol. 1994 Aug;130(8):1018-21 [8053698.001]
  • [Cites] Nat Genet. 1994 Sep;8(1):15-21 [7987387.001]
  • [Cites] Nat Genet. 1994 Dec;8(4):328-32 [7894481.001]
  • [Cites] Am J Hum Genet. 2001 Jan;68(1):64-80 [11112665.001]
  • [Cites] Br J Ophthalmol. 2001 Apr;85(4):420-3 [11264130.001]
  • [Cites] Cell. 2001 May 4;105(3):345-55 [11348591.001]
  • [Cites] Cell. 2001 May 4;105(3):357-68 [11348592.001]
  • [Cites] Mol Cell Biol. 2009 Aug;29(15):4250-61 [19451225.001]
  • [Cites] Nat Genet. 2009 Aug;41(8):920-5 [19578364.001]
  • [Cites] Nat Genet. 2009 Aug;41(8):915-9 [19578365.001]
  • [Cites] Annu Rev Genomics Hum Genet. 2009;10:45-61 [19405848.001]
  • [Cites] J Am Acad Dermatol. 2009 Oct;61(4):677.e1-14 [19751883.001]
  • [Cites] Cancer Res. 2009 Sep 15;69(18):7393-401 [19738042.001]
  • [Cites] N Engl J Med. 2009 Sep 17;361(12):1173-8 [19726761.001]
  • [Cites] N Engl J Med. 2009 Sep 17;361(12):1164-72 [19726763.001]
  • [Cites] Dermatol Surg. 2009 Oct;35(10):1576-81 [19681991.001]
  • [Cites] Lung Cancer. 2009 Nov;66(2):157-61 [19285750.001]
  • [Cites] Int J Cancer. 2010 Jan 15;126(2):563-71 [19634141.001]
  • [Cites] Cancer Prev Res (Phila). 2010 Jan;3(1):25-34 [20051370.001]
  • [Cites] Am J Hum Genet. 2007 Jan;80(1):140-51 [17160901.001]
  • [Cites] Science. 1996 Jun 14;272(5268):1668-71 [8658145.001]
  • [Cites] Cell. 1996 Jun 14;85(6):841-51 [8681379.001]
  • [Cites] Am J Hum Genet. 1996 Sep;59(3):529-39 [8751853.001]
  • [Cites] Nat Genet. 1996 Sep;14(1):78-81 [8782823.001]
  • [Cites] Cancer Res. 1996 Oct 15;56(20):4599-601 [8840969.001]
  • [Cites] Am J Hum Genet. 1997 Jan;60(1):21-6 [8981943.001]
  • [Cites] Am J Med Genet. 1997 Mar 31;69(3):299-308 [9096761.001]
  • [Cites] J Natl Cancer Inst. 1997 Aug 6;89(15):1103-9 [9262247.001]
  • [Cites] Am J Hum Genet. 1997 Oct;61(4):843-51 [9382094.001]
  • [Cites] Am J Med Genet. 1997 Dec 12;73(2):197-204 [9409873.001]
  • [Cites] Arch Dermatol. 1997 Dec;133(12):1539-43 [9420538.001]
  • [Cites] Nature. 1998 Jan 1;391(6662):90-2 [9422511.001]
  • [Cites] Hum Mol Genet. 1998 Feb;7(2):209-16 [9425228.001]
  • [Cites] Arch Neurol. 1998 Mar;55(3):379-84 [9520012.001]
  • [Cites] Hum Mol Genet. 1998 Jun;7(6):1053-7 [9580671.001]
  • [Cites] J Urol. 1998 Jul;160(1):141-5 [9628635.001]
  • [Cites] J Med Genet. 1998 Jun;35(6):450-5 [9643284.001]
  • [Cites] Hum Genet. 1998 May;102(5):598-601 [9654212.001]
  • [Cites] J Child Neurol. 1998 Dec;13(12):624-8 [9881533.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Jan;8(1):77-81 [9950243.001]
  • [Cites] J Child Neurol. 1999 Feb;14(2):71-4 [10073425.001]
  • [Cites] Am J Hum Genet. 1999 May;64(5):1305-15 [10205261.001]
  • [Cites] J Am Acad Dermatol. 1999 Jun;40(6 Pt 1):877-90; quiz 891-2 [10365918.001]
  • [Cites] J Child Neurol. 1999 Jun;14(6):401-7 [10385849.001]
  • [Cites] Semin Ophthalmol. 2008 Jan-Feb;23(1):45-51 [18214791.001]
  • [Cites] P R Health Sci J. 2007 Dec;26(4):349-54 [18246963.001]
  • [Cites] Mech Ageing Dev. 2008 Jan-Feb;129(1-2):35-47 [18160098.001]
  • [Cites] BMC Dermatol. 2008;8:1 [18226258.001]
  • [Cites] Int J Cancer. 2008 Jun 15;122(12):2753-60 [18366057.001]
  • [Cites] J Med Genet. 2008 May;45(5):284-9 [18178632.001]
  • [Cites] J Med Genet. 2008 May;45(5):303-8 [18285427.001]
  • [Cites] Ann Neurol. 2008 Apr;63(4):444-53 [18389497.001]
  • [Cites] Nat Genet. 2008 Jul;40(7):838-40 [18488026.001]
  • [Cites] Nat Genet. 2008 Jul;40(7):886-91 [18488027.001]
  • [Cites] Lancet. 2008 Aug 23;372(9639):657-68 [18722871.001]
  • [Cites] Mutat Res. 2008 Sep-Oct;659(3):284-92 [18598780.001]
  • [Cites] Eur J Med Genet. 2008 Sep-Oct;51(5):472-8 [18539553.001]
  • [Cites] Pediatrics. 2009 Jan;123(1):124-33 [19117870.001]
  • [Cites] Nat Genet. 2009 Feb;41(2):221-7 [19151717.001]
  • [Cites] Hum Mol Genet. 2009 Apr 15;18(R1):R94-100 [19297407.001]
  • [Cites] Hematol Oncol Clin North Am. 2009 Apr;23(2):215-31 [19327580.001]
  • [Cites] Eur J Neurol. 2009 Jun;16(6):691-6 [19236458.001]
  • [Cites] Hematol Oncol Clin North Am. 2009 Jun;23(3):383-95, vii [19464592.001]
  • [Cites] Lancet. 2009 Jun 6;373(9679):1974-86 [19476995.001]
  • [Cites] Br J Haematol. 2009 Apr;145(2):164-72 [19208095.001]
  • [Cites] J Am Acad Dermatol. 2009 Jul;61(1):1-14; quiz 15-6 [19539839.001]
  • [Cites] Am J Med Genet A. 2009 Jul;149A(7):1539-43 [19533801.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • (PMID = 20816579.001).
  • [ISSN] 1558-1977
  • [Journal-full-title] Hematology/oncology clinics of North America
  • [ISO-abbreviation] Hematol. Oncol. Clin. North Am.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 CP004410-31
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Review
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS352798; NLM/ PMC3276063
  •  go-up   go-down


3. Cózar MP, Ferrer-Rebolleda J, Redal MC, Moreno A, Tortajada L, Casáns I, Romero C: [Sentinel lymph node biopsy in cutaneous non-melanoma malignancies]. Rev Esp Med Nucl; 2006 Jan-Feb;25(1):10-4
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The SLN position was marked on the skin and after a correct localization in the surgical field with a gamma probe the SLN was obtained.
  • [MeSH-major] Lymphatic Metastasis / diagnosis. Sentinel Lymph Node Biopsy. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Carcinoma / diagnosis. Carcinoma / radionuclide imaging. Carcinoma / secondary. Carcinoma, Basal Cell / diagnosis. Carcinoma, Basal Cell / radionuclide imaging. Carcinoma, Basal Cell / secondary. Carcinoma, Merkel Cell / diagnosis. Carcinoma, Merkel Cell / radionuclide imaging. Carcinoma, Merkel Cell / secondary. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / radionuclide imaging. Carcinoma, Squamous Cell / secondary. Child. Dermatofibrosarcoma / diagnosis. Dermatofibrosarcoma / radionuclide imaging. Dermatofibrosarcoma / secondary. False Negative Reactions. Female. Humans. Male. Middle Aged. Radiopharmaceuticals. Retrospective Studies. Technetium Tc 99m Aggregated Albumin

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16540005.001).
  • [ISSN] 0212-6982
  • [Journal-full-title] Revista española de medicina nuclear
  • [ISO-abbreviation] Rev Esp Med Nucl
  • [Language] spa
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0 / Technetium Tc 99m Aggregated Albumin; 0 / technetium Tc 99m nanocolloid
  •  go-up   go-down


Advertisement
4. Pena T, LoRusso PM, Ruckdeschel JC, Goncalves P, Soubani AO: Pulmonary metastasis of basal cell carcinoma: a rare manifestation of a common disease with variable clinical course. J Thorac Oncol; 2009 Aug;4(8):1026-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary metastasis of basal cell carcinoma: a rare manifestation of a common disease with variable clinical course.
  • [MeSH-major] Carcinoma, Basal Cell / secondary. Lung Neoplasms / secondary. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / surgery. Prognosis

  • Genetic Alliance. consumer health - Pulmonary Disease.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19633477.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Mitcov M, Scrivener Y, Cribier B: [Desmoplastic trichoepithelioma: a clinicopathological study, including a comparison with morpheiform basal cell carcinoma]. Ann Dermatol Venereol; 2009 Jun-Jul;136(6-7):501-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Desmoplastic trichoepithelioma: a clinicopathological study, including a comparison with morpheiform basal cell carcinoma].
  • We carried out a retrospective histopathological study of a large series of cases of DTE in order to better characterise this tumour and compare it with sclerodermiform basal cell carcinoma (BCC), which is in fact the most common as well as the most complex type of differential diagnosis.
  • Diagnosis was confirmed by two different examiners and all microscopic elements were reviewed.
  • The diagnosis was only made by the clinician in four cases; in 38 cases the diagnosis made was BCC.
  • Mean clinical follow-up of 8 years (1 to 23 years) in 29 patients showed absence of relapse or metastasis.
  • A suggested clinical diagnosis is thus possible.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Neoplasms, Adnexal and Skin Appendage / pathology. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19560610.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


6. Garcia C, Poletti E, Crowson AN: Basosquamous carcinoma. J Am Acad Dermatol; 2009 Jan;60(1):137-43
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basosquamous carcinoma.
  • BACKGROUND: Basosquamous carcinoma is considered an aggressive type of basal cell carcinoma (BCC) with an increased risk of recurrence and metastases.
  • METHODS: This is a narrative review based on a MEDLINE search of articles in English and a manual search of popular dermatology textbooks to define basosquamous carcinoma, its incidence, clinical behavior, and treatment of choice.
  • RESULTS: There are no specific clinical features to distinguish basosquamous carcinoma from other BCC types and the diagnosis is made only after biopsy.
  • There are several histologic definitions of basosquamous carcinoma ranging from a characteristic combination of BCC and squamous cell carcinoma with or without a transition zone, to any BCC with evidence of keratinization.
  • The term "metatypical basal cell carcinoma" is considered a synonym but its use is discouraged for the reasons outlined.
  • The reported incidence of basosquamous carcinoma ranges from 1.2% to 2.7%.
  • The incidence of metastasis is at least 5%.
  • The aggressive biological behavior and clinical course distinguish basosquamous carcinoma from other forms of BCC.
  • CONCLUSION: The terminology surrounding basosquamous carcinoma is confusing and there is a need for more uniform language.
  • Data regarding the incidence, recurrence, and metastasis rates of basosquamous carcinoma are based mostly on retrospective series with a limited number of cases.
  • We conclude that although the incidence of basosquamous carcinoma is unknown, there is a literature precedent suggesting more aggressive biological behavior.
  • We believe that complete surgical excision is the preferred approach, and that basosquamous carcinoma is an ideal candidate lesion for Mohs micrographic surgery.
  • [MeSH-major] Carcinoma, Basosquamous. Skin Neoplasms

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for basosquamous carcinoma .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19103364.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 42
  •  go-up   go-down


7. Østergaard J, Boberg-Ans J, Prause JU, Heegaard S: Primary basal cell carcinoma of the caruncle with seeding to the conjunctiva. Graefes Arch Clin Exp Ophthalmol; 2005 Jun;243(6):615-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary basal cell carcinoma of the caruncle with seeding to the conjunctiva.
  • BACKGROUND: To report the clinical and histopathological characteristics of a patient with a primary basal cell carcinoma (BCC) of the caruncle with seeding of the tumour to the conjunctiva.
  • Clinical examination revealed a pale lobulated tumour without skin involvement.
  • Microscopically, both neoplasms were composed of infiltrative islands of basaloid tumour cells, scattered mitoses and peripheral palisading consistent with the diagnosis of BCC.
  • [MeSH-major] Carcinoma, Basal Cell / secondary. Conjunctival Neoplasms / secondary. Lacrimal Apparatus / pathology. Lacrimal Apparatus Diseases / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Eye Neoplasms / pathology. Eye Neoplasms / surgery. Fatal Outcome. Female. Humans. Middle Aged. Neoplasm Metastasis. Ophthalmologic Surgical Procedures / methods. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Tears.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surv Ophthalmol. 1993 Sep-Oct;38(2):169-92 [8235999.001]
  • [Cites] Arch Ophthalmol. 1998 Oct;116(10):1373-4 [9790642.001]
  • [Cites] Arch Ophthalmol. 2000 Sep;118(9):1296-8 [10980780.001]
  • [Cites] Br J Ophthalmol. 1973 Nov;57(11):836-7 [4785248.001]
  • [Cites] Am J Ophthalmol. 1982 Nov;94(5):591-3 [7148940.001]
  • [Cites] Ophthalmology. 1993 Nov;100(11):1720-2 [8233401.001]
  • [Cites] Cornea. 1987;6(2):78-116 [3301209.001]
  • [Cites] Indian J Ophthalmol. 1975 Oct;23(3):33-4 [1236314.001]
  • [Cites] Acta Ophthalmol Scand. 2000 Oct;78(5):547-52 [11037913.001]
  • [Cites] Arch Ophthalmol. 1997 Dec;115(12):1585-7 [9400796.001]
  • (PMID = 15614536.001).
  • [ISSN] 1435-702X
  • [Journal-full-title] Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
  • [ISO-abbreviation] Graefes Arch. Clin. Exp. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


8. Gabillot-Carré M, Weill F, Mamelle G, Kolb F, Boitier F, Petrow P, Ortoli JC, Margulis A, Souteyrand P, Mercier S, Spatz A, Duvillard P, Validire P, Avril MF: Microcystic adnexal carcinoma: report of seven cases including one with lung metastasis. Dermatology; 2006;212(3):221-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microcystic adnexal carcinoma: report of seven cases including one with lung metastasis.
  • BACKGROUND: Microcystic adnexal carcinoma (MAC) is a rare cutaneous neoplasm, with a high rate of local recurrences.
  • In 3 patients, the course of the disease was severe: one of them developed pathologically proven lung metastasis.
  • CONCLUSION: The present study and review of the literature confirm the clinically aggressive evolution of MAC and its rare ability to give rise to metastasis.
  • [MeSH-major] Carcinoma, Skin Appendage / pathology. Facial Neoplasms / pathology. Lung Neoplasms / secondary. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Carcinoma, Basal Cell / diagnosis. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local

  • Genetic Alliance. consumer health - Microcystic adnexal carcinoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2006 S. Karger AG, Basel
  • (PMID = 16549917.001).
  • [ISSN] 1018-8665
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


9. Elghissassi I, Mikou A, Inrhaoun H, Ennouhi A, Gamra L, Errihani H: Metastatic basal cell carcinoma to the bone and bone marrow. Int J Dermatol; 2009 May;48(5):481-3
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic basal cell carcinoma to the bone and bone marrow.
  • BACKGROUND: Basal cell carcinoma (BCC) is the most common carcinoma in the community, but the incidence of metastatic events is exceedingly low.
  • The few reported cases most often appear in regional nodes or the lungs, and patients usually exhibit multiple concurrent organs of spread at the time of diagnosis.
  • The bone marrow biopsy revealed metastasis of BCC.
  • CONCLUSION: Metastasis of BCC is a very rare condition that should not be overlooked.
  • [MeSH-major] Bone Marrow Neoplasms / secondary. Bone Neoplasms / secondary. Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / secondary. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19416377.001).
  • [ISSN] 1365-4632
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


10. Jani P, Chetty R, Ghazarian DM: An unusual composite pilomatrix carcinoma with intralesional melanocytes: differential diagnosis, immunohistochemical evaluation, and review of the literature. Am J Dermatopathol; 2008 Apr;30(2):174-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual composite pilomatrix carcinoma with intralesional melanocytes: differential diagnosis, immunohistochemical evaluation, and review of the literature.
  • We report a case of an extremely rare histologic combination of pilomatrix or pilomatrical carcinoma with admixed melanocytes within the same tumor mass.
  • Pilomatrix carcinoma is a neoplasm of low-grade malignancy that is characterized by a tendency for recurrence but low risk of metastasis.
  • In addition, intermingled with the pilomatrix carcinoma, several easily identified pigmented cells with dendritic processes were present singly and as small aggregates.
  • Pilomatrix carcinoma with melanocytes should be distinguished from the conventional pilomatrixoma with pigmentation, melanocytic matricoma, melanoma, and pigmented basal cell carcinoma with matrical differentiation.
  • Clinicians and pathologists should be aware of the occurrence of pilomatrix carcinoma with melanocytes because of its potential for diagnosis as melanoma.
  • [MeSH-major] Carcinoma, Skin Appendage / pathology. Hair Diseases / pathology. Melanocytes / pathology. Pilomatrixoma / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Biopsy, Needle. Diagnosis, Differential. Follow-Up Studies. Humans. Immunohistochemistry. Male. Neoplasm Staging. Nose. Risk Assessment. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hair Problems.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18360125.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 30
  •  go-up   go-down


11. Ntomouchtsis A, Vahtsevanos K, Patrikidou A, Andreadis C, Tsobanidou C, Antoniades K: Adnexal skin carcinomas of the face. J Craniofac Surg; 2009 Jan;20(1):134-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adnexal skin carcinomas of the face.
  • Skin adnexal neoplasms are rare tumors, and knowledge on their exact histological development and pathogenesis remains fragmented.
  • Their diagnosis and management are frequently troublesome, especially for malignant tumors.
  • Records of patients with histologically confirmed adnexal skin carcinoma managed at a single department during the period 1995 to 2004 were reviewed.
  • Patient biodata, surgical management, and main outcome measures such as locoregional recurrence, distant metastasis, and disease-free and overall survival were recorded.Eleven patients were identified from record analysis.
  • Two patients showed regional metastasis and underwent radical neck dissection.
  • Clinical and histological features, tumor biological behavior, diagnostic difficulties, and recommended management are discussed.In conclusion, adnexal skin tumors should be considered in the differential diagnosis of skin tumors, particularly in view of their more sinister prognosis compared with other nonmelanoma skin tumors.
  • [MeSH-major] Carcinoma, Skin Appendage / surgery. Facial Neoplasms / surgery. Skin Neoplasms / surgery
  • [MeSH-minor] Aged. Aged, 80 and over. Carcinoma, Basal Cell / diagnosis. Carcinoma, Squamous Cell / diagnosis. Cohort Studies. Diagnosis, Differential. Disease-Free Survival. Eyelid Neoplasms / surgery. Female. Follow-Up Studies. Humans. Lymphatic Metastasis / pathology. Male. Middle Aged. Neck Dissection. Neoplasm Recurrence, Local / pathology. Neoplasms, Second Primary / pathology. Nose Neoplasms / surgery. Retrospective Studies. Surgical Flaps. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19165010.001).
  • [ISSN] 1536-3732
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Ullah T, Gurwood AS, Myers MD: Ocular metastasis of cutaneous malignant melanoma. Optometry; 2009 Oct;80(10):572-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ocular metastasis of cutaneous malignant melanoma.
  • Although cutaneous malignancies include basal cell carcinoma, squamous cell carcinoma, sebaceous cell carcinoma, and malignant melanoma, the majority of cases that result in metastasis, ocular morbidity, and mortality are from sebaceous cell carcinoma and malignant melanoma.
  • Her systemic medical history was significant for the diagnosis of a cutaneous malignant melanoma.
  • Magnetic resonance imaging confirmed the diagnosis of metastatic lesions involving structures of the left orbit ultimately causing reduced visual ability.
  • Although orbital metastasis is considered a terminal finding in these cases, timely diagnosis enables, while limited, the best options for management.
  • [MeSH-major] Melanoma / secondary. Orbital Neoplasms / secondary. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Ocular melanoma.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19801341.001).
  • [ISSN] 1558-1527
  • [Journal-full-title] Optometry (St. Louis, Mo.)
  • [ISO-abbreviation] Optometry
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Eng TY, Boersma MG, Fuller CD, Goytia V, Jones WE 3rd, Joyner M, Nguyen DD: A comprehensive review of the treatment of Merkel cell carcinoma. Am J Clin Oncol; 2007 Dec;30(6):624-36
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A comprehensive review of the treatment of Merkel cell carcinoma.
  • Merkel cell carcinoma (MCC) is an uncommon but malignant cutaneous neuroendocrine carcinoma with a high incidence of local recurrence, regional lymph node metastases, and subsequent distant metastases.
  • It usually occurs in sun-exposed areas in elderly people, many of whom have a history of other synchronous or metachronous sun-associated skin lesions.
  • [MeSH-major] Carcinoma, Merkel Cell / therapy. Skin Neoplasms / therapy
  • [MeSH-minor] Aged. Carcinoma, Basal Cell / diagnosis. Carcinoma, Basal Cell / pathology. Diagnosis, Differential. Humans. Lymph Node Excision. Lymphatic Metastasis. Prognosis. Sentinel Lymph Node Biopsy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18091058.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 206
  •  go-up   go-down


14. Merritt BG, Snow SN, Longley BJ: Desmoplastic trichoepithelioma, infiltrative/morpheaform BCC, and microcystic adnexal carcinoma: differentiation by immunohistochemistry and determining the need for Mohs micrographic surgery. Cutis; 2010 May;85(5):254-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Desmoplastic trichoepithelioma, infiltrative/morpheaform BCC, and microcystic adnexal carcinoma: differentiation by immunohistochemistry and determining the need for Mohs micrographic surgery.
  • Desmoplastic trichoepithelioma (DTE), infiltrative/morpheaform basal cell carcinoma (BCC), and microcystic adnexal carcinoma (MAC) are tumors in this category that may be difficult to differentiate, especially when evaluating thin biopsy specimens.
  • An accurate diagnosis has important clinical implications.
  • While DTE is a benign neoplasm with indolent behavior, infiltrative/morpheaform BCC and MAC can be highly aggressive, leading to substantial local destruction and potential metastasis.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Skin Appendage / pathology. Mohs Surgery. Skin Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Humans. Immunohistochemistry. Keratin-20. Male. Middle Aged. Staining and Labeling

  • Genetic Alliance. consumer health - Microcystic adnexal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20540416.001).
  • [ISSN] 0011-4162
  • [Journal-full-title] Cutis
  • [ISO-abbreviation] Cutis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Keratin-20
  •  go-up   go-down


15. Otley CC: Non-Hodgkin lymphoma and skin cancer: A dangerous combination. Australas J Dermatol; 2006 Nov;47(4):231-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin lymphoma and skin cancer: A dangerous combination.
  • There is a significant association between non-Hodgkin lymphoma, including chronic lymphocytic leukaemia, and both melanoma and non-melanoma skin cancer.
  • This review highlights the existing data on the phenomenon of accelerated skin cancer in patients with non-Hodgkin lymphoma and specifically chronic lymphocytic leukaemia.
  • The outcomes of patients with non-Hodgkin lymphoma (including chronic lymphocytic leukaemia) and non-melanoma skin cancer are worse than in patients without concomitant lymphoreticular malignancy, as shown by increased rates of local recurrence, regional metastasis and death.
  • Pathogenic factors may be common between non-Hodgkin lymphoma and chronic lymphocytic leukaemia and skin cancer.
  • The treatment of skin cancer in patients with non-Hodgkin lymphoma must factor in the worse prognosis and adapt standard therapeutic approaches to minimize the risk of metastasis and death.
  • [MeSH-major] Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / therapy. Skin Neoplasms / diagnosis. Skin Neoplasms / therapy
  • [MeSH-minor] Carcinoma, Basal Cell / complications. Carcinoma, Basal Cell / diagnosis. Carcinoma, Basal Cell / physiopathology. Carcinoma, Basal Cell / therapy. Carcinoma, Merkel Cell / complications. Carcinoma, Merkel Cell / diagnosis. Carcinoma, Merkel Cell / physiopathology. Carcinoma, Merkel Cell / therapy. Carcinoma, Squamous Cell / complications. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / physiopathology. Carcinoma, Squamous Cell / therapy. Combined Modality Therapy. Humans. Melanoma / complications. Melanoma / diagnosis. Melanoma / physiopathology. Melanoma / therapy. Prognosis. Sarcoma, Kaposi / complications. Sarcoma, Kaposi / diagnosis. Sarcoma, Kaposi / physiopathology. Sarcoma, Kaposi / therapy. Xanthomatosis / complications. Xanthomatosis / diagnosis. Xanthomatosis / physiopathology. Xanthomatosis / therapy

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17034463.001).
  • [ISSN] 0004-8380
  • [Journal-full-title] The Australasian journal of dermatology
  • [ISO-abbreviation] Australas. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Australia
  • [Number-of-references] 44
  •  go-up   go-down


16. Vucetić B, Rogan SA, Hrabac P, Hudorović N, Cupić H, Lukinac L, Ledinsky M, Matejcić A, Lovricević I, Zekan M: Biological value of melanoma inhibitory activity serum concentration in patients with primary skin melanoma. Melanoma Res; 2008 Jun;18(3):201-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biological value of melanoma inhibitory activity serum concentration in patients with primary skin melanoma.
  • In addition, MIA serum levels were studied in two control groups; patients with dysplastic nevi and patients with basal cell carcinoma.
  • [MeSH-major] Extracellular Matrix Proteins / blood. Melanoma / blood. Melanoma / diagnosis. Neoplasm Proteins / blood. Skin Neoplasms / blood. Skin Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Biomarkers, Tumor / blood. Carcinoma, Basal Cell / blood. Carcinoma, Basal Cell / pathology. Dysplastic Nevus Syndrome / blood. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Predictive Value of Tests. Prognosis. Reference Values. Sensitivity and Specificity. Sentinel Lymph Node Biopsy

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18477894.001).
  • [ISSN] 0960-8931
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Extracellular Matrix Proteins; 0 / MIA protein, human; 0 / Neoplasm Proteins
  •  go-up   go-down


17. Plaza JA, Ortega PF, Stockman DL, Suster S: Value of p63 and podoplanin (D2-40) immunoreactivity in the distinction between primary cutaneous tumors and adenocarcinomas metastatic to the skin: a clinicopathologic and immunohistochemical study of 79 cases. J Cutan Pathol; 2010 Apr;37(4):403-10
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Value of p63 and podoplanin (D2-40) immunoreactivity in the distinction between primary cutaneous tumors and adenocarcinomas metastatic to the skin: a clinicopathologic and immunohistochemical study of 79 cases.
  • The distinction of metastatic carcinomas to the skin from poorly differentiated primary cutaneous carcinomas and sometimes primary benign adnexal tumors can pose a significant diagnostic challenge.
  • The purpose of this study was to evaluate the role of p63 and podoplanin (D2-40) immunoreactivity for separating primary skin tumors vs. cutaneous metastases of carcinomas from internal organs.
  • The 37 primary cutaneous tumors included 14 cases of benign adnexal tumors, 9 malignant skin adnexal neoplasms, and 14 primary squamous and basal cell carcinomas.
  • We found variable positivity with podoplanin in all primary cutaneous neoplasms including spiradenoma (6/6), hidradenoma (2/4), cylindroma (3/3), desmoplastic trichilemmoma (1/1), poorly differentiated squamous cell carcinoma (4/4), sebaceous carcinoma (1/1), basal cell carcinoma (4/10), trichilemmal carcinoma (2/2), eccrine carcinoma (3/3), microcystic adnexal carcinoma (1/1), adnexal carcinoma NOS (1/1), and porocarcinoma (1/1).
  • Sensitivity, specificity, and positive and negative predictive values of podoplanin and p63 immunoreactivity to separate primary skin neoplasms from metastatic carcinomas were 78.4, 100.0, 100.0 and 84.0% for podoplanin, respectively, and 100.0, 100.0, 100.0 and 100.0% for p63, respectively.
  • The differences in p63 and podoplanin immunohistochemical expression between primary skin tumors and metastatic carcinomas to the skin were statistically significant (p < 0, 0001).
  • The results of our study suggest that the combined expression of p63 and podoplanin are a useful adjunct for the diagnosis of skin tumors in the clinical setting of a questionable metastasis and may be relatively specific for distinguishing primary skin tumors from metastatic carcinomas to the skin.
  • [MeSH-major] Adenocarcinoma / metabolism. Membrane Glycoproteins / metabolism. Membrane Proteins / metabolism. Skin / metabolism. Skin Neoplasms / metabolism
  • [MeSH-minor] Diagnosis, Differential. Humans. Immunohistochemistry

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20377670.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / CKAP4 protein, human; 0 / Membrane Glycoproteins; 0 / Membrane Proteins; 0 / PDPN protein, human
  •  go-up   go-down


18. Satter EK, Derienzo DP: Synchronous onset of multiple cutaneous neuroendocrine (Merkel cell) carcinomas localized to the scalp. J Cutan Pathol; 2008 Jul;35(7):685-91
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous onset of multiple cutaneous neuroendocrine (Merkel cell) carcinomas localized to the scalp.
  • Merkel cell carcinoma (MCC) is a rare aggressive neoplasm that typically presents as a solitary nodule or plaque on sun-exposed skin of the elderly.
  • On low power, the tumor had the overall histological silhouette of a nodular basal cell carcinoma.
  • However, because of the lack of an epithelial connection and the cell's cytomorphological features, a MCC was considered and was subsequently confirmed using immunohistochemical stains.
  • [MeSH-major] Carcinoma, Merkel Cell / pathology. Skin / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Diagnosis, Differential. Humans. Lymph Nodes / pathology. Lymphatic Metastasis. Male. Middle Aged. Scalp / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18331571.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


19. Velazquez EF, Melamed J, Barreto JE, Aguero F, Cubilla AL: Sarcomatoid carcinoma of the penis: a clinicopathologic study of 15 cases. Am J Surg Pathol; 2005 Sep;29(9):1152-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sarcomatoid carcinoma of the penis: a clinicopathologic study of 15 cases.
  • A total of 400 cases of squamous cell carcinoma of the penis were reviewed from which 15 sarcomatoid carcinomas (4%) were identified.
  • Grossly, most tumors were large, polypoid, and ulcerated masses frequently affecting the glans (93%) and deeply invading corpora cavernosa (80%) and skin.
  • Four cases showed a minor mixed component of usual, papillary, verrucous, and basaloid carcinoma.
  • Intrapenile metastasis ("satellitosis") was present in 4 tumors.
  • One of the cases was multicentric with a separate independent focus of well-differentiated carcinoma with pseudohyperplastic features.
  • In conclusion, penile sarcomatoid carcinomas are unusual, large, and aggressive tumors usually associated with lymph node metastasis and poor outcome.
  • Diffuse immunoreactivity for p53, compared with a more basal and focal reactivity in differentiated squamous cell carcinoma, may be indicative of a late mutation in the natural progression of the disease.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Penile Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Diagnosis, Differential. Humans. Immunohistochemistry. In Situ Hybridization. Male. Middle Aged

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16096403.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


20. Eyden B, Moss J, Shore I, Banerjee SS: Metastatic small cell malignant melanoma: a case requiring immunoelectronmicroscopy for the demonstration of lattice-deficient melanosomes. Ultrastruct Pathol; 2005 Jan-Feb;29(1):71-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic small cell malignant melanoma: a case requiring immunoelectronmicroscopy for the demonstration of lattice-deficient melanosomes.
  • A case of metastatic malignant melanoma exhibiting small cell morphology is described.
  • The patient had had a previous primary nodular small cell melanoma.
  • Tumor cells were negative for S-100 protein and very focally positive for cytokeratin: these findings in combination with small cell morphology suggested the possibility of small cell carcinoma.
  • This is also the first case of small cell melanoma to be studied by electron microscopy.
  • [MeSH-major] Lymphatic Metastasis / pathology. Melanoma / pathology. Melanosomes / ultrastructure. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Aged. Carcinoma, Basal Cell / pathology. Diagnosis, Differential. Humans. Immunohistochemistry. Keratins / metabolism. Male. Microscopy, Electron, Transmission. Microscopy, Immunoelectron. Neoplasms, Multiple Primary / pathology. S100 Proteins / metabolism. Skin Neoplasms / metabolism. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15931781.001).
  • [ISSN] 0191-3123
  • [Journal-full-title] Ultrastructural pathology
  • [ISO-abbreviation] Ultrastruct Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / S100 Proteins; 68238-35-7 / Keratins
  •  go-up   go-down


21. Guenova E, Lichte V, Hoetzenecker W, Woelbing F, Moehrle M, Roecken M, Schaller M: Nodular malignant melanoma and multiple cutaneous neoplasms under immunosuppression with azathioprine. Melanoma Res; 2009 Aug;19(4):271-3
Hazardous Substances Data Bank. AZATHIOPRINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Immunosuppressed patients are at increased risk of skin cancer.
  • The patient died of metastatic disease 3 months after the diagnosis was made.
  • Renal transplant recipients are at high risk of developing nonmelanocytic skin tumors when on immunosuppressive therapy with cyclosporine A.
  • Less common is the development of skin cancer during immunosuppression with azathioprine.
  • Our case illustrates the necessity of close dermatological surveillance of allograft recipients, to assure an early recognition of any malignant skin tumor and to reduce the risk of systemic metastatic disease.
  • [MeSH-major] Azathioprine / adverse effects. Immunosuppressive Agents / adverse effects. Kidney Transplantation. Melanoma / etiology. Neoplasms, Multiple Primary / etiology. Skin Neoplasms / etiology
  • [MeSH-minor] Aged. Antineoplastic Agents, Alkylating / therapeutic use. Carcinoma, Basal Cell / etiology. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / etiology. Carcinoma, Squamous Cell / pathology. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Drug Therapy, Combination. Early Detection of Cancer. Humans. Lymphatic Metastasis. Male. Splenic Neoplasms / secondary

  • Genetic Alliance. consumer health - Nodular melanoma.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19550360.001).
  • [ISSN] 1473-5636
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Immunosuppressive Agents; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; MRK240IY2L / Azathioprine
  •  go-up   go-down


22. Chiu CS, Lin CY, Kuo TT, Kuan YZ, Chen MJ, Ho HC, Yang LC, Chen CH, Shih IH, Hong HS, Chuang YH: Malignant cutaneous tumors of the scalp: a study of demographic characteristics and histologic distributions of 398 Taiwanese patients. J Am Acad Dermatol; 2007 Mar;56(3):448-52
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Age at diagnosis, sex, and histologic types were analyzed.
  • Age at diagnosis ranged from 3 to 103 years.
  • Basal (41.2%) and squamous (16.6%) cell carcinomas were the most common histologic types.
  • LIMITATIONS: In our series, the case number of metastatic scalp malignancies was underestimated because not all patients with metastatic scalp tumors received a scalp skin biopsy.
  • CONCLUSION: Because a wide spectrum of primary and metastatic malignancies can occur on the scalp, scalp inspection should be included in general screening for either skin or internal cancers.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Head and Neck Neoplasms / epidemiology. Scalp. Skin Neoplasms / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Aged, 80 and over. Child. Child, Preschool. Dermatofibrosarcoma / epidemiology. Female. Hemangiosarcoma / epidemiology. Humans. Incidence. Lung Neoplasms / epidemiology. Lung Neoplasms / secondary. Male. Middle Aged. Neoplasm Metastasis. Retrospective Studies. Sex Distribution. Taiwan / epidemiology

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17141358.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


23. Combemale P, Bousquet M, Kanitakis J, Bernard P, Angiodermatology Group, French Society of Dermatology: Malignant transformation of leg ulcers: a retrospective study of 85 cases. J Eur Acad Dermatol Venereol; 2007 Aug;21(7):935-41
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For squamous cell carcinomas (SCC), the duration of the ulcer had to be longer than 3 years.
  • For basal cell carcinomas (BCC), a negative previous biopsy of the ulcer was considered.
  • The high death rate, especially in metastatic cases, is at least partly due to delay in diagnosis.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Leg Ulcer / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Amputation. Cell Transformation, Neoplastic. Female. France / epidemiology. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Retrospective Studies. Surveys and Questionnaires

  • MedlinePlus Health Information. consumer health - Leg Injuries and Disorders.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17659003.001).
  • [ISSN] 0926-9959
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


24. Filippou DK, Filippou G, Trigka A, Condilis N, Kiparidou E, Skandalakis P, Rizos S: Malignant proliferating trichilemmal tumour of the scalp. Report of a case and a short review of the literature. Ann Ital Chir; 2006 Mar-Apr;77(2):179-81
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Malignant proliferating trichilemmal tumour is a rare skin tumour that originates from the root sheath of the hair and usually arises in the sun-exposed areas of elderly women.
  • It mimicks poorly differential squamous cell carcinoma ant its biological behaviour is unpredictable, because rarely can produce distant metastases.
  • In the reported case, although the high risk of distant metastasis, two years after the tumour resection the patient is free of disease, It is also reported a short review of the literature.
  • The appropriate treatment includes wide resection and dose postoperative follow-up of the patient to facilitate the early diagnosis of distant metastases.
  • [MeSH-major] Neoplasms, Basal Cell / surgery. Scalp. Skin Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17147095.001).
  • [ISSN] 0003-469X
  • [Journal-full-title] Annali italiani di chirurgia
  • [ISO-abbreviation] Ann Ital Chir
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


25. Kazakov DV, Vittay G, Michal M, Calonje E: High-grade trichoblastic carcinosarcoma. Am J Dermatopathol; 2008 Feb;30(1):62-4
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumor was excised, and the patient had no evidence of recurrence or metastasis 6 years after surgery.
  • We view the present case and that previously reported in 2004 as authentic carcinosarcomas, and not as metaplastic (sarcomatoid) basal cell carcinomas.
  • [MeSH-major] Carcinosarcoma / pathology. Hair Diseases / pathology. Hair Follicle / pathology. Neoplasms, Adnexal and Skin Appendage / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged, 80 and over. Carcinoma, Basal Cell / pathology. Diagnosis, Differential. Ear / pathology. Humans. Immunohistochemistry. Male

  • MedlinePlus Health Information. consumer health - Hair Problems.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18212548.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Minimizing surgery in skin cancer treatment. A new test looks for cancer in the lymph nodes during melanoma surgery, while a topical cream helps people with another form of skin cancer avoid the knife. Health News; 2005 Feb;11(2):12-3
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimizing surgery in skin cancer treatment. A new test looks for cancer in the lymph nodes during melanoma surgery, while a topical cream helps people with another form of skin cancer avoid the knife.
  • [MeSH-major] Carcinoma, Basal Cell / drug therapy. Melanoma / surgery. Skin Neoplasms / drug therapy. Skin Neoplasms / surgery
  • [MeSH-minor] Adjuvants, Immunologic / therapeutic use. Aminoquinolines / therapeutic use. Antibodies, Neoplasm. Antineoplastic Agents / therapeutic use. Biomarkers, Tumor / analysis. Humans. Lymphatic Metastasis / diagnosis

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15732154.001).
  • [ISSN] 1081-5880
  • [Journal-full-title] Health news (Waltham, Mass.)
  • [ISO-abbreviation] Health News
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 99011-02-6 / imiquimod
  •  go-up   go-down






Advertisement